Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis
Free AI-powered analysis and research for Ultragenyx Pharmaceutical Inc. stock
Sector: Healthcare
Full RARE report
Ultragenyx Pharmaceutical Inc. (RARE) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze RARE Now βπ° Latest Update
Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...
Thu, November 5, 2026 at 5:03 PM UTC 3 min read
Ultragenyx Pharmaceutical Inc (RARE) reaffirmed its 2026 total revenue guidance of $730 million to $760 million, driven by growth from established products and the recent FDA approval of two new gene therapies, GENGLYCOS and FAYUVI. The company is projecting full-year GAAP net income profitability in 2027, supported by significant expense reductions and approximately $350 million in non-dilutive capital from the sale of two Priority Review Vouchers. However, RARE is discontinuing its GTX-102 and UX701 programs due to efficacy failures, leading to a 20% workforce reduction.